Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy Volunteers (Meningococcal Infection)MeningitisMeningococcal InfectionsMeningococcal Meningitis

Phase 3

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

CompletedNCT03077438

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2017-02-17End: 2017-10-10Updated: 2022-03-28

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico

CompletedNCT03630705

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2018-10-17End: 2022-02-18Updated: 2023-10-19

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

CompletedNCT03691610

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2018-10-04End: 2023-10-20Updated: 2024-06-25

Related Papers

Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6–23 months: phase III study (US/Puerto Rico)

Pediatric Research2026-03-06

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

2026-01-01

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

2026-01-01

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.

2025-12-01

P-662. Phase III, modified double-blind, randomized, parallel group, active-controlled, multi-center study of Meningococcal quadrivalent ACWY conjugated vaccine in infants from 6 through 23 months of age in the United States

Open Forum Infectious Diseases2025-01-29

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2–9 Years of Age: A Phase III, Randomized Study

The Pediatric Infectious Disease Journal2020-08-2123 citations

2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)

Open Forum Infectious Diseases2019-10-013 citations